Bioneer’s Combination Tests for SARS-CoV-2 and Influenza Receive CE-IVD Marking
By HospiMedica International staff writers Posted on 19 Nov 2020 |
AccuPower RV1 Real-Time RT-PCR Kit (Photo courtesy of Bioneer)
Bioneer (Daejeon, Korea) has received CE-IVD marking for two combination tests for SARS-CoV-2 and influenza - the AccuPower RV1 Real-Time RT-PCR Kit and AccuPower RV1 Multiplex Kit.
The AccuPower RV1 Real-Time RT-PCR Kit is an in vitro diagnostic kit that helps diagnose COVID-19 and Influenza infections. The 5-in-1 multiplex kit is able to detect five COVID-19 targets (E gene, RdRp & N gene) and Influenza A/B in a tube using samples collected via a nasopharyngeal swab or oropharyngeal swab taken from suspected infected patients. The easy-to-use multiplex kit reduces hands-on steps due to five-target multiplex detection in a tube. The user-convenient premix type kit enables pipetting free diagnosis since all the components for the assay are contained within a tube. It uses Bioneer’s proprietary Dual-HotStart technology to achieve high sensitivity and specificity, and the vacuum-dried premix allows for stable and reproducible results. The test kit is compatible with the ExiStation and ExiStation 48 systems.
The AccuPower RV1 Multiplex Kit is an in vitro diagnostic kit that helps diagnose COVID-19 and Influenza infections. The kit is able to detect five COVID-19 targets (E gene, RdRp & N gene) and Influenza A/B in a tube using samples collected via a nasopharyngeal swab or oropharyngeal swab taken from suspected infected patients. The easy-to-use multiplex kit reduces hands-on steps due to five-target multiplex detection in a tube and uses Bioneer’s proprietary Dual-HotStart technology to achieve high sensitivity and specificity. The test kit is compatible with various systems, including Exicycler 96 (BIONEER), CFX 96 (Bio-rad), ABI7500 Fast (Thermofisher), and Quantstudio 5 (Thermofisher).
The AccuPower RV1 Real-Time RT-PCR Kit is an in vitro diagnostic kit that helps diagnose COVID-19 and Influenza infections. The 5-in-1 multiplex kit is able to detect five COVID-19 targets (E gene, RdRp & N gene) and Influenza A/B in a tube using samples collected via a nasopharyngeal swab or oropharyngeal swab taken from suspected infected patients. The easy-to-use multiplex kit reduces hands-on steps due to five-target multiplex detection in a tube. The user-convenient premix type kit enables pipetting free diagnosis since all the components for the assay are contained within a tube. It uses Bioneer’s proprietary Dual-HotStart technology to achieve high sensitivity and specificity, and the vacuum-dried premix allows for stable and reproducible results. The test kit is compatible with the ExiStation and ExiStation 48 systems.
The AccuPower RV1 Multiplex Kit is an in vitro diagnostic kit that helps diagnose COVID-19 and Influenza infections. The kit is able to detect five COVID-19 targets (E gene, RdRp & N gene) and Influenza A/B in a tube using samples collected via a nasopharyngeal swab or oropharyngeal swab taken from suspected infected patients. The easy-to-use multiplex kit reduces hands-on steps due to five-target multiplex detection in a tube and uses Bioneer’s proprietary Dual-HotStart technology to achieve high sensitivity and specificity. The test kit is compatible with various systems, including Exicycler 96 (BIONEER), CFX 96 (Bio-rad), ABI7500 Fast (Thermofisher), and Quantstudio 5 (Thermofisher).
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans